Antibody Response to SARS-CoV-2 Infection in Non Vaccinated Health Care Personnel

Background: Antibodies (Abs) are produced by B cells after infection with the SARS/COVID-19 virus. The presence of neutralizing antibody is an indicator of protective immunity for most viral infections. But, we still don’t know how long and how effectively this immune protection will cover. Objectives: This study aimed to estimate the antibodies level in PCR-confirmed COVID-19 subjects in non vaccinated healthcare personnel. Methods: SARS-CoV-2 specific total Abs (IgG and IgM), IgG of nucleocapsid (N) protein and spike (S) protein levels were estimated using two clinically validated and widely used serological assays, detecting antibodies against the Total Antibody, nucleocapsid(N) and spike(S) proteins. Results: A total 130 subjects with PCR-confirmed SARSCoV- 2 infection were included in this study and all subjects were symptomatic and blood samples were collected between 3 to 24 weeks. Of all participants, about 52% were female and mean age was 43.2 years. The study found that the Total Abs, IgG of N protein and neutralizing Abs of S protein were developed 100%, 74.6% and 93.8% respectively. The study also found that the IgG titers of the N protein peaked at about 19 weeks after onset and decreased thereafter. The study also found that the neutralizing Abs of S protein were gradually increasing in the second phase of (9wks-19wks) weeks and in the third phase of (19wks -24wks) weeks after disease onset than compared to the first phase of weeks (3wks- 9wks) and it was significant (p<0.001). Conclusion: The study concluded that the antibodies, total Abs, IgG titer of N protein and neutralizing Abs of S protein were developed 100%, 74.6% and 93.8% respectively. The study also observed that IgG of N protein was decreasing within 19-24 weeks and neutralizing Abs of S protein peaked at 19-24 weeks after the onset of disease. [ FROM AUTHOR] Copyright of Journal of Bangladesh College of Physicians & Surgeons is the property of Bangladesh College of Physicians & Surgeons and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis.

BACKGROUND: Current guidelines recommend vaccination against SARS-CoV2 for people with multiple sclerosis (pwMS). The long-term review of the safety and effectiveness of COVID-19 vaccines in pwMS is limited. METHODS: Service re-evaluation. PwMS using the MS service at Barts Health National Health Service Trust were sent questionnaires via email to report symptoms following first and second COVID-19 vaccinations (n = 570). A retrospective review of electronic health records was conducted for clinical and safety data post-vaccination(s); cut-off was end of September 2021. Separate logistic regressions were carried out for symptoms experienced at each vaccination. Two sets of regressions were fitted with covariates: (i) Disease-modifying therapy type and (ii) patient characteristics for symptoms experienced. RESULTS: 193/570 pwMS responded. 184 pwMS had both vaccinations. 144 received the AZD1222 and 49 the BNT162b2 vaccine. 87% and 75% of pwMS experienced any symptoms at first and second vaccinations, respectively. The majority of symptoms resolved within a short timeframe. No severe adverse effects were reported. Two pwMS subsequently died; one due to COVID-19 and one due to aspiration pneumonia. Males were at a reduced risk of reporting symptoms at first vaccination. There was evidence that pwMS in certain treatment groups were at reduced risk of reporting symptoms at second vaccination only. CONCLUSIONS: Findings are consistent with our preliminary data. Symptoms post-vaccination were similar to the non-MS population and were mostly temporary. It is important to inform the MS community of vaccine safety data.

An evaluation of remote monitoring in people with MS during the COVID-19 pandemic

Introduction: The COVID-19 pandemic caused major disruption to health services across the Globe, including the UK. Quick adaptations were required to switch from face-to-face to remote consultations and to further develop remote monitoring (RM) of people with multiple sclerosis (pwMS) in the community. Objective: To evaluate the views of pwMS under the care of our team who participated in RM. Methods: RM included completion of the nine-hole peg test, Timed 25-foot walk, ABILHAND questionnaire and WebEDSS at home. Electronic health records were queried for pwMS who participated in RM from May 2020-July 2020. Questionnaires (N=72) were sent via post or email asking about their experience of RM. Data were analysed using descriptive statistics. This service evaluation project was registered with the clinical effectiveness unit at Barts Health NHS Trust (Registration:11945). Results: 23 pwMS (mean age 49 years (SD11.7);18 women, 5 men;relapsing MS: 17;progressive MS: 6;EDSS 0-8) responded to the survey. The majority viewed RM as a way for healthcare professionals to provide pwMS with the necessary support (83%) and to manage MS symptoms (70%);65% were keen to know more about how RM scores can be used to help them manage their MS symptoms. Overall, 60% of respondents felt confident completing assessments at home;52% said they will continue with RM after the pandemic. Conclusions: RM enabled monitoring of pwMS during the pandemic. Results suggest pwMS understood and generally agreed with the intentions of RM. There is also evident potential to facilitate patient activation and self-management. The apparent reluctance to continue RM in half of our sample after the pandemic warrants further exploration. Whilst bias may play a role due to limited returns, further reasons may include lack of digital confidence and associated risk of health inequalities.

Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis.

BACKGROUND: Some people with multiple sclerosis (pwMS) are at increased risk of severe Coronavirus disease 19 (COVID-19) and should be rapidly vaccinated. However, vaccine supplies are limited, and there are concerns about side-effects, particularly with the ChAdOx1nCoV-19 (AstraZeneca) vaccine. OBJECTIVES: To report our first experience of pwMS receiving the AstraZeneca vaccine. METHODS: Service evaluation. pwMS using the MS service at Barts Health NHS Trust were sent questionnaires to report symptoms following vaccination. RESULTS: Thirty-three responses were returned, 29/33 pwMS received a first dose of AstraZeneca vaccine, the remaining four received a first dose of BioNTech/Pfizer vaccine. All but two patients (94%) reported any symptoms including a sore arm (70%), flu-like symptoms (64%), fever (21%), fatigue (27%), and headache (21%). In more than 2/3 patients, symptoms lasted up to 48 hours, and with the exception of two pwMS reporting symptom duration of 10 and 12 days, respectively, symptoms in the remainder resolved within seven days. No severe adverse effects occurred. CONCLUSIONS: pwMS report transient symptoms following AstraZeneca vaccination, characteristics of which were similar to those reported in the non-MS population. Symptoms may be more pronounced in pwMS due to the temperature-dependent delay in impulse propagation (Uhthoff's phenomenon) due to demyelination.